Maxim Group Cuts Autonomix Medical (NASDAQ:AMIX) Price Target to $2.00

Autonomix Medical (NASDAQ:AMIX) had its target price decreased by research analysts at Maxim Group from $5.00 to $2.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Maxim Group’s target price indicates a potential upside of 446.45% from the company’s previous close.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Autonomix Medical in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $2.00.

Autonomix Medical Price Performance

Autonomix Medical stock traded down $0.02 during trading on Tuesday, reaching $0.37. 161,536 shares of the company were exchanged, compared to its average volume of 1,834,889. The stock’s 50 day simple moving average is $0.52 and its two-hundred day simple moving average is $0.88. The company has a market capitalization of $2.53 million, a P/E ratio of -0.10 and a beta of -2.57. Autonomix Medical has a 52-week low of $0.34 and a 52-week high of $3.09.

Autonomix Medical (NASDAQ:AMIX) last issued its earnings results on Wednesday, February 11th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.10. As a group, equities analysts forecast that Autonomix Medical will post -10 earnings per share for the current year.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.